Wall Street brokerages expect Ionis Pharmaceuticals Inc (NASDAQ:IONS) to post $132.40 million in sales for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Ionis Pharmaceuticals’ earnings. The highest sales estimate is $141.50 million and the lowest is $124.70 million. Ionis Pharmaceuticals posted sales of $120.91 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 9.5%. The firm is expected to report its next earnings results on Tuesday, November 6th.
On average, analysts expect that Ionis Pharmaceuticals will report full year sales of $573.35 million for the current financial year, with estimates ranging from $529.30 million to $661.00 million. For the next financial year, analysts anticipate that the business will post sales of $790.84 million, with estimates ranging from $465.63 million to $1.26 billion. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that that provide coverage for Ionis Pharmaceuticals.
Ionis Pharmaceuticals (NASDAQ:IONS) last released its quarterly earnings data on Tuesday, August 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.20). The firm had revenue of $117.75 million for the quarter, compared to analyst estimates of $128.22 million. Ionis Pharmaceuticals had a negative net margin of 7.20% and a negative return on equity of 1.22%.
In other Ionis Pharmaceuticals news, SVP C Frank Bennett sold 12,500 shares of the firm’s stock in a transaction dated Wednesday, August 8th. The stock was sold at an average price of $45.00, for a total transaction of $562,500.00. Following the transaction, the senior vice president now directly owns 19,409 shares in the company, valued at $873,405. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, COO Brett P. Monia sold 16,493 shares of Ionis Pharmaceuticals stock in a transaction dated Monday, August 27th. The stock was sold at an average price of $54.00, for a total value of $890,622.00. Following the completion of the transaction, the chief operating officer now owns 24,834 shares in the company, valued at $1,341,036. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 29,149 shares of company stock worth $1,460,459. Corporate insiders own 2.44% of the company’s stock.
Institutional investors have recently bought and sold shares of the company. Point72 Asia Hong Kong Ltd increased its stake in shares of Ionis Pharmaceuticals by 255.8% in the first quarter. Point72 Asia Hong Kong Ltd now owns 2,498 shares of the company’s stock worth $110,000 after purchasing an additional 1,796 shares during the period. Clarus Wealth Advisors increased its stake in Ionis Pharmaceuticals by 200.0% during the third quarter. Clarus Wealth Advisors now owns 3,600 shares of the company’s stock valued at $186,000 after acquiring an additional 2,400 shares during the period. Rockefeller Capital Management L.P. bought a new position in Ionis Pharmaceuticals during the second quarter valued at about $156,000. TLP Group LLC increased its stake in Ionis Pharmaceuticals by 5,220.0% during the first quarter. TLP Group LLC now owns 4,522 shares of the company’s stock valued at $199,000 after acquiring an additional 4,437 shares during the period. Finally, Cambridge Investment Research Advisors Inc. bought a new position in Ionis Pharmaceuticals during the second quarter valued at about $212,000. Institutional investors and hedge funds own 85.55% of the company’s stock.
IONS traded up $1.63 during trading on Friday, reaching $45.00. 911,740 shares of the stock traded hands, compared to its average volume of 1,146,997. The stock has a market cap of $7.08 billion, a price-to-earnings ratio of 562.50 and a beta of 2.43. Ionis Pharmaceuticals has a fifty-two week low of $39.07 and a fifty-two week high of $65.51. The company has a current ratio of 8.38, a quick ratio of 8.34 and a debt-to-equity ratio of 0.76.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein.
Read More: How to interpret a stock’s beta number
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.